| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w14634 |
| 来源ID | Working Paper 14634 |
| The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation | |
| Guy David; Sara Markowitz; Seth Richards | |
| 发表日期 | 2009-01-08 |
| 出版年 | 2009 |
| 语种 | 英语 |
| 摘要 | This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug events by modeling the interaction between a welfare maximizing regulator (the FDA) and a profit maximizing firm. In our analysis demand is sensitive to both promotion and regulatory interventions. Promotion-driven market expansions enhance profitability yet may involve the risk that the drug would be prescribed inappropriately, leading to adverse regulatory actions against the firm. The model exposes the effects of the current regulatory system on consumer and producer welfare. Particularly, the emphasis on safety over benefits distorts the market allocation of drugs away from some of the most appropriate users. We then empirically test the relationship between drug promotion and reporting of adverse reactions using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and adverse drug reactions. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of adverse medical events for certain conditions. |
| 主题 | Health, Education, and Welfare ; Health ; Other ; Law and Economics |
| URL | https://www.nber.org/papers/w14634 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/572308 |
| 推荐引用方式 GB/T 7714 | Guy David,Sara Markowitz,Seth Richards. The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation. 2009. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w14634.pdf（296KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
